Key Highlights

  • Consensus EPS of 2.24 sits within management's third-quarter adjusted diluted EPS guidance range of 2.20 to 2.25.
  • Consensus revenue of USD 934.36 million compares with second-quarter net sales of USD 920.6 million, against USD 865.4 million.
  • Management raised 2026 adjusted EPS guidance to 8.70 to 8.85 and organic growth guidance to 5% to 6%.
  • Orders were USD 1,071.6 million, up 29% on a reported basis, with organic order growth of 28%.

IDEX (NYSE:IEX) reports third-quarter results on Wednesday, Oct. 28, before the market opens. Consensus stands at EPS of 2.24 on revenue of USD 934.36 million, and the company has a market capitalization of USD 17.03 billion.

IDEX makes engineered products across its Health and Science Technologies, Fluid and Metering Technologies and Fire and Safety and Diversified Products segments. Second-quarter net sales were USD 920.6 million against USD 865.4 million, and net income was USD 143.4 million against USD 131.6 million.

Estimates Against Third-Quarter Guidance

Management guided third-quarter adjusted diluted EPS of 2.20 to 2.25 and organic growth of 5% to 7%. The EPS estimate of 2.24 sits inside that range, and the estimates table does not state its EPS basis. The revenue estimate of USD 934.36 million is above the USD 920.6 million of second-quarter net sales.

Second-quarter diluted EPS was 1.93 against 1.74, and adjusted diluted EPS was 2.32, up 12%. An IEEPA tariff refund added 0.08 per share, including interest and a reduction to cost of sales.

What Management Guided and What It Left Open

Management raised 2026 organic growth guidance to 5% to 6% from 3% to 4%, adjusted diluted EPS guidance to 8.70 to 8.85 from 8.35 to 8.55 and adjusted EBITDA margin guidance to 27% to 27.3% from 26.5% to 27%. Capital expenditures are now forecast at USD 110 million, up from USD 90 million.

Management left open the pace of orders in the Health and Science Technologies segment, which it tied to data center, semiconductor and space and defense demand. It also noted customer rebates of USD 14.7 million that reduced net sales as part of sharing tariff refunds.

Orders and Segment Margins

Orders of USD 1,071.6 million rose 29% on a reported basis. Organic orders grew 47% in Health and Science Technologies, 11% in Fluid and Metering Technologies and 19% in Fire and Safety and Diversified Products.

Adjusted EBITDA margin was 28.1%, up 70 basis points. Health and Science Technologies margin was 28.7%, up 270 basis points, and Fluid and Metering Technologies margin was 34.8%, down 20 basis points as mix offset productivity.

Earnings Lines and Capital Return

Net income was USD 143.4 million against USD 131.6 million, and basic EPS was 1.94 against 1.74. Gross profit was USD 426.8 million against USD 392.2 million, and operating income was USD 199.9 million against USD 187.9 million. Income before income taxes was USD 186.1 million against USD 169.9 million.

Free cash flow was USD 177 million against USD 146.9 million. The company repurchased USD 77 million of shares, up 53%, and paid USD 54 million in dividends. The estimates table lists a market capitalization of USD 17.03 billion.

Comparisons to Make in the Report

Reported EPS against 2.24 and net sales against USD 934.36 million are the headline comparisons. Other markers are orders, tariff refund effects and the 2026 guidance ranges.